Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Chief Medical Officer | March 26, 2026 | March 27, 2026 |
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Chief Medical Officer | March 04, 2022 | March 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protagonist Therapeutics, Inc
Report date March 26, 2026 · Filed March 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 84,115 |
Ending reported balance
After 2026-03-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-26 · Exercise / conversion · Acquired 15,000 · Balance 99,115 Row 2 · 2026-03-26 · Sale · Disposed 15,000 · Balance 84,115 F1: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $103.99 to $105.54. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.04 · Expires 2032-11-15 | Direct | 50,971 |
Reported balance
After 2026-03-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-26 · Exercise / conversion · Disposed 15,000 · Balance 50,971 F2: The stock option was granted to the Reporting Person on November 7, 2022, one quarter vested on November 7, 2023 and the remaining three quarters vest in equal monthly installments through November 7, 2026, subject to the Reporting Person's continuous service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $103.99 to $105.54. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2: The stock option was granted to the Reporting Person on November 7, 2022, one quarter vested on November 7, 2023 and the remaining three quarters vest in equal monthly installments through November 7, 2026, subject to the Reporting Person's continuous service to the Issuer.
SUTRO BIOPHARMA, INC.
Report date March 04, 2022 · Filed March 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,736 |
Ending reported balance
After 2022-03-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-05 · Exercise / conversion · Acquired 12,500 · Balance 42,091 F1: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Row 2 · 2022-03-05 · Tax withholding · Disposed 4,355 · Balance 37,736 F2: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.17 · Expires 2032-03-03 | Direct | 52,000 |
Reported balance
After 2022-03-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-04 · Grant · Acquired 52,000 · Balance 52,000 F3: The option vests as to 2.0833% of the total shares monthly, beginning on April 4, 2022, with 100% of the total shares vested and exercisable on March 4, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2026-03-04 | Direct | 39,000 |
Reported balance
After 2022-03-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-04 · Grant · Acquired 39,000 · Balance 39,000 F1: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2025-03-05 | Direct | 37,500 |
Reported balance
After 2022-03-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-03-05 · Exercise / conversion · Disposed 12,500 · Balance 37,500 F1: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F2: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.
F3: The option vests as to 2.0833% of the total shares monthly, beginning on April 4, 2022, with 100% of the total shares vested and exercisable on March 4, 2026, subject to the reporting person's provision of service to the issuer on each vesting date.
F4: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date.
F5: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Forma Therapeutics Holdings, Inc.
Report date October 14, 2022 · Filed October 14, 2022
Section 16 reporting ended · disclosed 2022-10-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 1
1 source rowRow 1 · 2022-10-14 · Other · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F2: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.97 | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-14 · Disposition to issuer · Disposed 16,750 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.12 | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-14 · Disposition to issuer · Disposed 6,750 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest.
F2: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 26, 2026 Filed Mar 27, 2026 23:36 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001104659-26-036319 · tm2610129-3_4seq1.xml · derivative · entry 3 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,971 Underlying: Common Stock · 15,000 shares Expires 2032-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option was granted to the Reporting Person on November 7, 2022, one quarter vested on November 7, 2023 and the remaining three quarters vest in equal monthly installments through November 7, 2026, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 23:36 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 15,000 | $104.79 | $1,571,850.00 |
DisclosureSEC source: 0001104659-26-036319 · tm2610129-3_4seq1.xml · nonDerivative · entry 2 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,115 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $103.99 to $105.54. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 23:36 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 15,000 | $8.04 | $120,600.00 |
DisclosureSEC source: 0001104659-26-036319 · tm2610129-3_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:19 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001104659-26-007127 · tm264253-1_4seq1.xml · derivative · entry 7 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,971 Underlying: Common Stock · 5,000 shares Expires 2032-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:19 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 5,000 | $82.00 | $410,000.00 |
DisclosureSEC source: 0001104659-26-007127 · tm264253-1_4seq1.xml · nonDerivative · entry 5 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,115 Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:19 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 5,000 | $8.04 | $40,200.00 |
DisclosureSEC source: 0001104659-26-007127 · tm264253-1_4seq1.xml · nonDerivative · entry 4 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 02:19 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001104659-26-007127 · tm264253-1_4seq1.xml · derivative · entry 6 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,971 Underlying: Common Stock · 5,000 shares Expires 2032-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 02:19 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 5,000 | $82.28 | $411,400.00 |
DisclosureSEC source: 0001104659-26-007127 · tm264253-1_4seq1.xml · nonDerivative · entry 3 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,115 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.14 to $82.55. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 02:19 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 5,000 | $8.04 | $40,200.00 |
DisclosureSEC source: 0001104659-26-007127 · tm264253-1_4seq1.xml · nonDerivative · entry 2 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2026 Filed Jan 28, 2026 02:19 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 13,151 | $82.42 | $1,083,905.42 |
DisclosureSEC source: 0001104659-26-007127 · tm264253-1_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,115 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.665 to $84.64. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 22:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 9,514 | $82.48 | $784,714.72 |
DisclosureSEC source: 0001104659-26-005443 · tm263774-3_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,266 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:35 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $87.18 | $0.00 |
DisclosureSEC source: 0001104659-26-001471 · tm262304-1_4seq1.xml · derivative · entry 2 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2036-01-02 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:35 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 25,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-001471 · tm262304-1_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,780 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:01 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 2,712 | $84.77 | $229,896.24 |
DisclosureSEC source: 0001104659-25-114082 · tm2531619-1_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,180 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:40 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001104659-25-058597 · tm2517775-1_4seq1.xml · derivative · entry 6 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,971 Underlying: Common Stock · 10,000 shares Expires 2032-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:40 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 10,000 | $57.03 | $570,300.00 |
DisclosureSEC source: 0001104659-25-058597 · tm2517775-1_4seq1.xml · nonDerivative · entry 4 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,892 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $56.665 to $57.48. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:40 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 10,000 | $8.04 | $80,400.00 |
DisclosureSEC source: 0001104659-25-058597 · tm2517775-1_4seq1.xml · nonDerivative · entry 3 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 21:40 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001104659-25-058597 · tm2517775-1_4seq1.xml · derivative · entry 5 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,971 Underlying: Common Stock · 10,000 shares Expires 2032-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 21:40 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 10,000 | $55.51 | $555,100.00 |
DisclosureSEC source: 0001104659-25-058597 · tm2517775-1_4seq1.xml · nonDerivative · entry 2 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,892 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.18 to $55.75. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 21:40 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 10,000 | $8.04 | $80,400.00 |
DisclosureSEC source: 0001104659-25-058597 · tm2517775-1_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 22:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 2,077 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-024063 · tm259281-2_4seq1.xml · derivative · entry 5 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,785 Underlying: Common Stock · 2,077 shares Expires 2035-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 22:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 28,437 | $0.00 Strike: $23.42 | $0.00 |
DisclosureSEC source: 0001104659-25-024063 · tm259281-2_4seq1.xml · derivative · entry 4 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,063 Underlying: Common Stock · 28,437 shares Expires 2034-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 22:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 30,514 | $55.74 | $1,700,850.36 |
DisclosureSEC source: 0001104659-25-024063 · tm259281-2_4seq1.xml · nonDerivative · entry 3 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,892 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.245 to $56.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 22:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 2,077 | $38.98 | $80,961.46 |
DisclosureSEC source: 0001104659-25-024063 · tm259281-2_4seq1.xml · nonDerivative · entry 2 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 22:21 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 28,437 | $23.42 | $665,994.54 |
DisclosureSEC source: 0001104659-25-024063 · tm259281-2_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2025 Filed Jan 17, 2025 22:47 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 3,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004571 · tm253633-3_4seq1.xml · nonDerivative · entry 2 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,892 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| January 16, 2025 Filed Jan 17, 2025 22:47 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 388 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004571 · tm253633-3_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,144 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:06 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 49,862 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-001427 · tm252003-2_4seq1.xml · derivative · entry 2 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,862 Underlying: Common Stock · 49,862 shares Expires 2035-01-02 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:06 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 41,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-001427 · tm252003-2_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,532 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| November 27, 2024 Filed Nov 28, 2024 00:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · derivative · entry 9 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,971 Underlying: Common Stock · 16,000 shares Expires 2032-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 27, 2024 Filed Nov 28, 2024 00:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · derivative · entry 8 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,971 Underlying: Common Stock · 10,000 shares Expires 2032-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 27, 2024 Filed Nov 28, 2024 00:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 16,000 | $44.83 | $717,280.00 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · nonDerivative · entry 6 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,444 F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $44.50 to $44.99. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 27, 2024 Filed Nov 28, 2024 00:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 16,000 | $8.04 | $128,640.00 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · nonDerivative · entry 5 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2024 Filed Nov 28, 2024 00:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 10,000 | $44.50 | $445,000.00 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · nonDerivative · entry 4 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,444 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $43.80 to $44.92. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 27, 2024 Filed Nov 28, 2024 00:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 10,000 | $8.04 | $80,400.00 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · nonDerivative · entry 3 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 5,529 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · derivative · entry 7 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,971 Underlying: Common Stock · 5,529 shares Expires 2032-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 5,529 | $45.60 | $252,122.40 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · nonDerivative · entry 2 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,444 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.94. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:11 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 5,529 | $8.04 | $44,453.16 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 23:49 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 1,906 | $40.98 | $78,107.88 |
DisclosureSEC source: 0001104659-24-120670 · tm2428939-1_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,444 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| January 16, 2024 Filed Jan 19, 2024 01:00 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Tax withholdingCommon Stock | 427 | $24.63 | $10,517.01 |
DisclosureSEC source: 0001104659-24-004901 · tm243616-2_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,350 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 1,041 restricted stock units on January 15, 2024. Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 01:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 97,500 | $0.00 Strike: $23.42 | $0.00 |
DisclosureSEC source: 0001104659-24-001490 · tm241954-2_4seq1.xml · derivative · entry 3 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 97,500 shares Expires 2034-01-02 F3 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 01:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-001490 · tm241954-2_4seq1.xml · nonDerivative · entry 2 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,777 F2 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in three equal annual installments on January 15, 2025, 2026 and 2027, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| November 15, 2023 Filed Jan 5, 2024 01:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 1,848 | $16.24 | $30,011.52 |
DisclosureSEC source: 0001104659-24-001490 · tm241954-2_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,527 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| January 16, 2023 Filed Jan 19, 2023 00:51 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-23-004722 · tm233829-5_4seq1.xml · derivative · entry 2 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2033-01-15 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| January 16, 2023 Filed Jan 19, 2023 00:51 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004722 · tm233829-5_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,375 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on January 15, 2024, 2025 and 2026. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 23:22 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 127,500 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001104659-22-119971 · tm2230775-2_4seq1.xml · derivative · entry 2 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,500 Underlying: Common Stock · 127,500 shares Expires 2032-11-15 F2 · derivative.exercise_date: The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which will vest on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 23:22 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 21,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-119971 · tm2230775-2_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 F1 · shares: Represents grant of restricted stock units payable solely in shares of the Issuer's common stock that will vest in four annual installments on November 15, 2023, 2024, 2025 and 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 16:07 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,750 | Not disclosed Strike: $6.12 | Not disclosed |
DisclosureSEC source: 0000899243-22-033655 · doc4.xml · derivative · entry 3 MOLINA ARTURO MD · CIK 0001398940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,750 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 16:07 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,750 | Not disclosed Strike: $11.97 | Not disclosed |
DisclosureSEC source: 0000899243-22-033655 · doc4.xml · derivative · entry 2 MOLINA ARTURO MD · CIK 0001398940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,750 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 16:07 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | OtherCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033655 · doc4.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F2 · kind: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. F2 · shares: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. F2 · price: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.